Boekhoff, Immo

[["dc.bibliographiccitation.firstpage","3283"],["dc.bibliographiccitation.issue","51-52"],["dc.bibliographiccitation.journal","Deutsches Ärzteblatt"],["dc.bibliographiccitation.lastpage","3286"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Ratzka, P."],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Boekhoff, Immo"],["dc.contributor.author","Poser, Sigrid"],["dc.contributor.author","Prange, Hilmar Walter"],["dc.date.accessioned","2017-11-21T12:33:49Z"],["dc.date.available","2017-11-21T12:33:49Z"],["dc.date.issued","1998"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/10140"],["dc.language.iso","de"],["dc.notes.status","final"],["dc.title","Therapeutische Ansätze bei der Creutzfeldt-Jakob-Krankheit"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","171"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Neuroscience Letters"],["dc.bibliographiccitation.lastpage","173"],["dc.bibliographiccitation.volume","240"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Bahn, Erik"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Boekhoff, Immo"],["dc.contributor.author","Beuche, Wolfgang"],["dc.date.accessioned","2017-09-07T11:44:38Z"],["dc.date.available","2017-09-07T11:44:38Z"],["dc.date.issued","1998"],["dc.description.abstract","Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown origin characterized by loss of upper and lower motor neurons and concomitant astrogliosis. We have investigated the S100 beta protein levels in serum as a marker for astroglia of patients with ALS (n=41) in comparison to a control group (n=32). Additionally we have investigated 12 patients at different follow-up time points (minimum 6 months). We could not observe a significant difference of S100 beta protein in patients with ALS in comparison to our control group (P=0.11) but we could clearly see a decrease of S100 beta levels in the further course of the disease. As S100 beta is also seen as a protein with nerve growth factor activity we assume that the fall of serum levels may reflect the loss of nerve growth stimulation in patients with ALS and suppose that repetitive measurements of S100 beta in serum can be used as an objective marker for disease progression."],["dc.identifier.doi","10.1016/s0304-3940(97)00947-6"],["dc.identifier.gro","3151715"],["dc.identifier.pmid","9502231"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8535"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.relation.issn","0304-3940"],["dc.title","Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S131"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neurobiology of Aging"],["dc.bibliographiccitation.lastpage","S132"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Ratzka, P."],["dc.contributor.author","Doehlinger, S."],["dc.contributor.author","Boekhoff, I."],["dc.contributor.author","Poser, Sigrid"],["dc.contributor.author","Prange, Hilmar"],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Irle, W."],["dc.contributor.author","Pergande, G."],["dc.contributor.author","Eller-Lenz, B."],["dc.contributor.author","Windl, Otto"],["dc.contributor.author","Kretzschmar, Hans A."],["dc.date.accessioned","2018-11-07T10:23:11Z"],["dc.date.available","2018-11-07T10:23:11Z"],["dc.date.issued","2002"],["dc.identifier.isi","000177465300486"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42407"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","0197-4580"],["dc.title","Efficacy of flupirtine on cognitive function in patients with Creutzfeldt-Jakob-disease"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","714"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","718"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Otto, M."],["dc.contributor.author","Cepek, L."],["dc.contributor.author","Ratzka, P."],["dc.contributor.author","Doehlinger, S."],["dc.contributor.author","Boekhoff, I."],["dc.contributor.author","Wiltfang, J."],["dc.contributor.author","Irle, E."],["dc.contributor.author","Pergande, G."],["dc.contributor.author","Ellers-Lenz, B."],["dc.contributor.author","Prange, H."],["dc.date.accessioned","2021-06-01T10:48:09Z"],["dc.date.available","2021-06-01T10:48:09Z"],["dc.date.issued","2004"],["dc.description.abstract","Background: In cell culture experiments, flupirtine maleate ( FLU), a triaminopyridine compound, was able to protect neuronal cells from apoptotic cell death induced by prion protein fragments and beta-amyloid peptides. As FLU is a clinically safe drug, the authors started a double-blind placebo-controlled study in patients with Creutzfeldt - Jakob disease (CJD). Methods: Twenty-eight patients with CJD were randomized to an oral treatment with either FLU ( n = 13) or matching placebo (PLA; n = 15). For inclusion and continuing the study, the patients had to achieve at least 50% in two of the subscales of the dementia tests employed. A battery of standardized questionnaires was employed to monitor the progression of the disease. The main outcome variable was the cognitive part of the Alzheimer's Disease Assessment Scale (ADAS-Cog); the difference between baseline and the best score under treatment was defined as the primary efficacy variable for hypothesis testing. Results: CJD types were homogeneously distributed among the treatment groups. Patients treated with FLU showed significantly less deterioration in the dementia tests than patients treated with PLA. The mean change in ADAS-Cog ( baseline to best) was + 8.4 ( +/- 15.3) in the FLU group and + 20.6 ( +/- 15.1) in the PLA group ( p = 0.02, one-sided t-test). Conclusions: FLU has beneficial effects on cognitive function in patients with CJD. These positive results also may suggest a treatment potential of FLU in other neurodegenerative disorders. However, further studies are necessary."],["dc.identifier.doi","10.1212/01.WNL.0000113764.35026.EF"],["dc.identifier.isi","000220083000008"],["dc.identifier.pmid","15007119"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85845"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.eissn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]